GANIRELIX ACETATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for GANIRELIX ACETATE (GANIRELIX ACETATE).
Comprehensive clinical and safety monograph for GANIRELIX ACETATE (GANIRELIX ACETATE).
Inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)Off-label: Treatment of hormone-sensitive cancers (e.g., prostate cancer) when rapid suppression of gonadotropins is needed
Gonadotropin-releasing hormone (GnRH) antagonist competitively blocks GnRH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
| Metabolism | Primarily hepatically metabolized via peptide hydrolysis; no major CYP450 involvement. |
| Excretion | Renal (approximately 75% as unchanged drug and metabolites) and fecal (approximately 22%). |
| Half-life | Terminal elimination half-life is approximately 16.2 hours (range 11-19 hours) in healthy females; clinically supports once-daily dosing. |
| Protein binding | Approximately 90%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Approximately 0.9 L/kg, indicating distribution primarily into extracellular fluid and some tissue binding. |
| Bioavailability | Subcutaneous: Approximately 100% (range 91-100%) relative to intravenous injection. |
| Onset of Action | Subcutaneous: Within 1 hour, serum gonadotropin levels begin to decline. |
| Duration of Action | Subcutaneous: Duration of suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) is approximately 12-24 hours, supporting daily administration during controlled ovarian hyperstimulation. |
| Molecular Weight | 1570.4 |
250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of hCG administration.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. No data for severe renal impairment (CrCl < 30 mL/min). |
| Liver impairment | No clinical data for hepatic impairment. Use with caution in moderate to severe hepatic impairment. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Not approved for use in geriatric patients. |
| 1st trimester | Contraindicated due to risk of pregnancy disruption; potential teratogenic effects unknown but theoretical risk exists. |
| 2nd trimester | Contraindicated; may interfere with hormone-dependent processes. |
| 3rd trimester | Contraindicated; no indication in pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for GANIRELIX ACETATE (GANIRELIX ACETATE).
| Placental transfer | Limited data; likely minimal due to high molecular weight and peptide structure. |
| Breastfeeding | Minimal excretion expected due to short half-life and peptide nature; however, no human data available. Discontinue breastfeeding or drug based on necessity. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) due to hormonal disruption. |
| Fetal Monitoring | Monitor for signs of pregnancy prior to initiation. If exposure occurs during pregnancy, ultrasound for fetal development and assess for pregnancy loss. |
| Fertility Effects | Inhibits ovulation; used in controlled ovarian stimulation. Reversibly impairs fertility during treatment; long-term reproductive effects not established. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to ganirelix acetate or any excipientPregnancyPostmenopausal statusSevere hepatic impairmentSevere renal impairment
| Precautions | Hypersensitivity reactions (urticaria, angioedema) have been reported, Ovarian hyperstimulation syndrome (OHSS) may occur with ART, Congenital abnormalities cannot be excluded; pregnancy should be excluded before use |
| Food/Dietary | No significant food interactions. Grapefruit may theoretically affect metabolism but data are lacking; caution is advised. |
| Clinical Pearls | Administer subcutaneously in the abdomen. Rotate injection sites to prevent lipodystrophy. Monitor for ovarian hyperstimulation syndrome (OHSS) especially in patients with polycystic ovary syndrome. Use caution in patients with renal impairment. |
| Patient Advice | Inject exactly as prescribed, typically once daily during the stimulation phase. · Do not skip doses; missed doses may reduce effectiveness. · Report severe pelvic pain, nausea, vomiting, or rapid weight gain immediately. · Store at room temperature (20-25°C) and protect from light. · Use within 30 days after first use. |
Loading safety data…